Update of polymyxin treatment for refractory bacterial infections

Chinese Journal of Infection and Chemotherapy

Volumn 7, Issue 6, 2007, Pages 464-467

  Lu, Jian ^a  

^a SHENZHEN THIRD PEOPLE S HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; CEFEPIME; CEFTAZIDIME; CIPROFLOXACIN; COLISTIMETHATE; COLISTIN; POLYMYXIN; POLYMYXIN B; SULTAMICILLIN;

ACINETOBACTER BAUMANNII; ACUTE KIDNEY FAILURE; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL INFECTION; BACTERIUM ISOLATE; CRITICALLY ILL PATIENT; EVIDENCE BASED MEDICINE; GRAM NEGATIVE INFECTION; HUMAN; KIDNEY DYSFUNCTION; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NEPHROTOXICITY; NONHUMAN; OUTCOME ASSESSMENT; PSEUDOMONAS AERUGINOSA; TREATMENT DURATION;

EID: 37849003875     PISSN: 10097708     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Livermore DM. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? [J]. Clin Infect Dis, 2002, 34(5): 634-640.
2. Hsueh PR, Teng LJ, Chen CY, et al. Pandrug-resistant Acinetobacter baumannii causing nosocomial infections in a university hospital, Taiwan[J]. Emerg Infect Dis, 2002, 8(8): 827-832.
3. Evans ME, Feola DJ, Rapp RP. Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant gram-negative bacteria[J]. Ann Pharmacother, 1999, 33 (9): 960-967.
4. Gales AC, Jones RN, Sader HS. Global assessment of the antimicrobial activity of polymyxin B against 54731 clinical isolates of Gram-negative bacilli: report from the SENTRY antimicrobial surveillance programme (2001-2004) [J]. Clin Microbiol Infect, 2006, 12(4): 315-321.
5. Falagas ME, Kasiakou SK, Tsiodras S, et al. The use of intravenous and aerosolized polymyxins for the treatment of infections in critically ill patients: a review of the recent literature[J]. Clin Med Res, 2006, 4(2): 138-146.
6. Gough M, Hancock RE, Kelly NM. Antiendotoxin activity of cationic peptide antimicrobial agents [J]. Infect Immun, 1996, 64(12): 4922-4927.
7. Gales AC, Reis AO, Jones RN. Contemporary assessment of antimicrobial susceptibility testing methods for polymyxin B and colistin: review of available interpretative criteria and quality control guidelines[J]. J Clin Microbiol, 2001, 39(1): 183-190.
8. Li J, Nation RL, Milne RW, et al. Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria[J]. Int J Antimicrob Agents, 2005, 25(1): 11-25.
9. Tam VH, Schilling AN, Vo G, et al. Pharmacodynamics of polymyxin B against Pseudomonas aeruginosa[J]. Antimicrob Agents Chemother, 2005, 49(12): 3624-3630.
10. Markou N, Apostolakos H, Koumoudiou C, et al. Intravenous colistin in the treatment of sepsis from multiresistant Gram-negative bacilli in critically ill patients[J]. Crit Care, 2003, 7(5): R78-R83.
11. Kasiakou SK, Michalopoulos A, Soteriades ES, et al. Combination therapy with intravenous colistin for management of infections due to multidrug-resistant Gram negative bacteria in patients without cystic fibrosis[J]. Antimicrob Agents Chemother, 2005, 49(8): 3136-3146.
12. Michalopoulos AS, Tsiodras S, Rellos K, et al. Colistin treatment in patients with ICU-acquired infections caused by multiresistant Gram-negative bacteria: the renaissance of an old antibiotic [J]. Clin Microbiol Infect, 2005, 11(2): 115-121.
13. Falagas ME, Rizos M, Bliziotis IA, et al. Toxicity after prolonged (more than four weeks) administration of intravenous colistin[J]. BMC Infect Dis, 2005, 5(1): 1.
14. Sobieszczyk ME, Furuya EY, Hay CM, et al. Combination therapy with polymyxin B for the treatment of multidrug-resistant Gram-negative respiratory tract infections[J]. J Antimicrob Chemother, 2004, 54(2): 566-569.
15. Michalopoulos A, Kasiakou SK, Mastora Z, et al. Aerosolized colistin for the treatment of nosocomial pneumonia due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis[J]. Crit Care, 2005, 9(1): R53-R59.
16. Kwa AL, Loh C, Low JG, et al. Nebulized colistin in the treatment of pneumonia due to multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa[J]. Clin Infect Dis, 2005, 41(5): 754-757.
17. Berlana D, Llop JM, Fort E, et al. Use of colistin in the treatment of multiple-drug-resistant gram-negative infections [J]. Am J Health Syst Pharm, 2005, 62(1): 39-47.
18. Hamer DH. Treatment of nosocomial pneumonia and tracheobronchitis caused by multidrug-resistant Pseudomonas aeruginosa with aerosolized colistin[J]. Am J Respir Crit Care Med, 2000, 162(1): 328-330.
19. Lewis JR, Lewis SA. Colistin interactions with the mammalian urothelium[J]. Am J Physiol Cell Physiol, 2004, 286(4): C913-C922.
20. Cunningham S, Prasad A, Collyer L, et al. Bronchoconstriction following nebulised colistin in cystic fibrosis[J]. Arch Dis Child, 2001, 84(5): 432-433.